The impact of inpatient rehabilitation on progressive multiple sclerosis

Annals of Neurology

Volumn 42, Issue 2, 1997, Pages 236-244

  Freeman, J A ^a   Langdon, D W ^a   Hobart, J C ^a   Thompson, A J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITAL PATIENT; HUMAN; INDEPENDENCE; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF CARE; TREATMENT OUTCOME;

ADULT; AGED; COGNITION DISORDERS; CONFIDENCE INTERVALS; DISABILITY EVALUATION; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; ORIENTATION; RECURRENCE; REPRODUCIBILITY OF RESULTS; SOCIAL BEHAVIOR; TREATMENT OUTCOME; WALKING; WHEELCHAIRS;

EID: 0030811122     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420216     Document Type: Article

References (54)

1. Thompson AJ. Multiple sclerosis: symptomatic treatment. J Neurol 1996;243:559-565
2. Thompson AJ, McDonald WI. Multiple sclerosis and its pathophysiology. In: Diseases of the nervous system. Asbury AK, McKhann GM, McDonald WI, ed. Philadelphia: WB Saunders, 1992:1209-1228
3. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989;112:133-146
4. Wcinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36(Suppl):S6-S11
5. Poser S, Kurtzke JF, Poser W, Schlaf G. Survival in multiple sclerosis. J Clin Epidemiol 1989;42:159-168
6. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Econ 1995;8:181-193
7. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS: final outcome of the randomised controlled trial. Neurology 1995;45:1277-1285
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase 3 multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
9. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon β-Ia for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
10. Thompson AJ, Noseworthy JH. New treatments for multiple sclerosis: a clinical perspective. Curr Opin Neurol 1996;9:187-198
11. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134
12. Devinsky O. Outcome research in neurology: incorporating health-related quality of life. Ann Neurol 1995;37:141-142
13. Johnson KB. Exercise, drug treatment, and the optimal care of multiple sclerosis patients. Ann Neurol 1996;39:422-423
14. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996;39:432-441
15. British Society of Rehabilitation Medicine. Multiple sclerosis (working party report). London: Royal College of Physicians, 1993
16. Schapiro RT. The rehabilitation of multiple sclerosis. J Neurol Rehabil 1990;4:215-217
17. Tallis R. Measurement and the future of rehabilitation. Geriatr Med 1989;January:31-40
18. Langton Hewer R. Multiple sclerosis - management and rehabilitation. Int J Rehabil Med 1980;2:116-125
19. Erickson RP, Lie MR, Wineinger MA. Rehabilitation in multiple sclerosis. Mayo Clin Proc 1989;64:818-828
20. La Rocca NG, Kalb RC. Efficacy of rehabilitation in multiple sclerosis. J Neurol Rehabil 1992;6:147-155
21. Feigenson JS, Scheinberg L, Catalano M, et al. The cost-effectiveness of multiple sclerosis rehabilitation: a model. Neurology 1981;31:1316-1322
22. Greenspun B, Stineman M, Agri R. Multiple sclerosis and rehabilitation outcome. Arch Phys Med Rehabil 1987;68:434-437
23. Reding MJ, La Rocca NG. Acute-hospital care versus rehabilitation hospitalisation for management of nonemergent complications in multiple sclerosis. J Neurol Rehabil 1987;1:13-17
24. Carey RG, Seibert JH. Who makes the most progress in inpatient rehabilitation? an analysis of functional gain. Arch Phys Med Rehabil 1988;69:337-343
25. Francabandera FL, Holland NJ, Wiesel-Levison P, Scheinberg LC. Multiple sclerosis rehabilitation: inpatient versus outpatient. Rehabil Nursing 1988;13:251-253
26. Kidd D, Howard RS, Losseff NA, Thompson AJ. The benefit of inpatient neurorehabilitation in multiple sclerosis. Clin Rehabil 1995;9:198-203
27. Aisen ML, Sevilla D, Fox N. Inpatient rehabilitation for multiple sclerosis. J Neurol Rehabil 1996;10:43-46
28. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
29. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911
30. Freeman JA, Playford ED, Nicholas RS, Thompson AJ. A neurological rehabilitation unit: audit of activity and outcome. J R Coll Phys Lond 1996;30:21-26
31. Johnson J, Thompson AJ. Rehabilitation in a neuroscience centre: the tole of expert assessment and selection. Br J Ther Rehabil 1996;3:303-308
32. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1444-1452
33. World Health Organization. International classification of impairments, disabilities and handicaps. Geneva: WHO, 1980
34. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988;38:1793-1798
35. Slater RJ. Criteria and uses of the minimal record of disability in multiple sclerosis. Acta Neurol Scand Suppl 1984;70:16-20
36. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47
37. Noseworthy JH, Vandervoort MK, Hopkins M, Ebers GC. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop. Neurology 1989;39:977-981
38. Hobart JC, Lamping DL, Freeman JA, Thompson AJ. Reliability, validity and responsiveness of the Kurtzke expanded disability status scale (EDSS) in multiple sclerosis. Eur J Neurol 1996; 3:13 (Abstract)
39. Granger CV, Cotter AC, Hamilton BB, et al. Functional assessment scales: a study of persons with multiple sclerosis. Arch Phys Med Rehabil 1990;71:870-875
40. Brosseau L, Wolfson C. The inter-rater reliability and construct validity of the functional independence measure for multiple sclerosis subjects. Clin Rehabil 1994;8:107-115
41. Harwood RH, Ebrahim S. Manual of the London handicap scale. Nottingham: University of Nottingham, Department of Health Care of the Elderly, 1995
42. La Rocca NG, Schapiro RT, Scheinberg LC, Kraft GH. Comprehensive care in multiple sclerosis: the whole versus the parts. J Neurol Rehabil 1994;8:95-98
43. Schapiro RT, Langer SL. Symptomatic therapy of multiple sclerosis. Curr Opin Neurol 1994;7:229-233
44. Scheinberg L, Holland NJ, Kirschenbaum M, et al. Comprehensive long-term care of patients with multiple sclerosis. Neurology 1981;31:1121-1123
45. Mertin J. Rehabilitation in multiple sclerosis. Ann Neurol 1994;36(Suppl):S130-S133
46. Kazis L, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-S188
47. Cohen J. The concepts of power analysis. In: Statistical power analysis for the behavioural sciences. London: Academic Press, 1977:1-20
48. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 1987;40:171-178
49. Hobart JC, Thompson AJ. Clinical trials of multiple sclerosis. In: Reader AT, ed. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997:449-508
50. Noseworthy JH. Immunosuppressive therapy in multiple sclerosis: pros and cons. Int MS J 1996;1:79-89
51. Noseworthy JH. Clinical scoring methods for multiple sclerosis. Ann Neurol 1994;36(Suppl):S80-S85
52. Fuller KJ, Dawson K, Wiles CM. Physiotherapy in chronic multiple sclerosis: a controlled trial. Clin Rehabil 1996;10:195-204
53. Noseworthy JH, Ebers GV, Vandervoort MK, et al. The impact of blinding on the results of a randomised, placebo-controlled multiple sclerosis clinical trial. Neurology 1994;44: 16-20
54. Fuhrer MJ. Overview of outcome analysis in rehabilitation. In: Fuhrer MJ, ed. Rehabilitation outcomes: analysis and measurement. London: Paul Brookes, 1987:1-15